Gaviscon Double Action Mint Chewable Tablets

Brand History and Evolution

Gaviscon is a globally recognized pharmaceutical brand that specializes in the treatment of gastroesophageal reflux disease (GERD) and heartburn. The brand's origin dates back to the mid-20th century, specifically being developed in the United Kingdom. It is famous for its unique 'raft-forming' action, which creates a physical barrier on top of the stomach contents to prevent acid from rising into the esophagus.

Ownership and Global Presence

The brand is owned by Reckitt Benckiser (now known as Reckitt), a British multinational consumer goods company. Although Reckitt owns the global rights to Gaviscon, there are unique licensing arrangements in North America (specifically the United States), where the brand is marketed by Haleon (formerly GlaxoSmithKline) under license. This specific packaging is characteristic of the UK and European markets managed directly by Reckitt.

Manufacturing and Composition

Manufacturing for the European and British markets primarily takes place in the United Kingdom, notably at Reckitt’s major pharmaceutical facility in Hull. The product's double-action formula combines sodium alginate, sodium bicarbonate, and calcium carbonate to both neutralize excess stomach acid and provide a protective barrier. As one of the world's leading over-the-counter remedies, Gaviscon maintains a high standard of pharmaceutical compliance across its various global production sites.